Skip to main content

Table 2 Event distribution according to the studied classifications

From: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death

 

Overall (n = 493)

No endpoint (n = 470)

Endpoint (n = 23)

p-value

HCM Risk-SCD

   

0.018

 Low risk, n (%)

362 (73.4%)

351 (74.7%)

11 (47.8%)

 Intermediate risk, n (%)

66 (13.4%)

59 (12.6%)

7 (30.4%)

 High risk, n (%)

65 (13.2%)

60 (12.8%)

5 (21.7%)

 Risk at 5-years (%)

2.5 (1.7–4.1)

2.4 (1.7–4.0)

4.2 (2.4–6.0)

0.003

ACCF/AHA

   

0.075

 ICD not recommended, n (%)

281 (57.0%)

273 (58.1%)

8 (34.8%)

 ICD can be useful, n (%)

68 (13.8%)

62 (13.2%)

6 (26.1%)

 ICD reasonable, n (%)

144 (29.2%)

135 (28.7%)

9 (39.1%)

LGE classification

   

<  0.001

 0%, n (%)

102 (20.7%)

102 (21.7%)

0 (0%)

 0.1–10.0%, n (%)

285 (57.8%)

279 (59.4%)

6 (26.1%)

 10.1–19.9%, n (%)

63 (12.8%)

55 (11.7%)

8 (34.8%)

  ≥ 20%, n (%)

43 (8.7%)

34 (7.2%)

9 (39.1%)

  1. Continuous variables presented as mean ± standard deviation or median (25th – 75th percentiles) where appropriate
  2. ACCF/AHA American College of Cardiology Foundation / American Heart Association, HCM Risk-SCD hypertrophic cardiomyopathy sudden cardiac death risk tool, LGE late gadolinium enhancement